CORT Corcept Therapeutics Inc

Price (delayed)

$20.29

Market cap

$2.37B

P/E Ratio

23.59

Dividend/share

N/A

EPS

$0.86

Enterprise value

$2.32B

Highlights
Corcept Therapeutics's debt has decreased by 34% YoY and by 19% QoQ
The P/E is 38% less than the 5-year quarterly average of 38.3 but 3% more than the last 4 quarters average of 22.9
The company's equity rose by 25% YoY but it fell by 2.4% QoQ
The EPS has declined by 7% since the previous quarter and by 7% year-on-year
CORT's net income is down by 6% QoQ and by 6% YoY

Key stats

What are the main financial stats of CORT
Market
Shares outstanding
116.63M
Market cap
$2.37B
Enterprise value
$2.32B
Valuations
Price to earnings (P/E)
23.59
Price to book (P/B)
4.66
Price to sales (P/S)
6.97
EV/EBIT
21.03
EV/EBITDA
20.59
EV/Sales
6.81
Earnings
Revenue
$340.06M
EBIT
$110.13M
EBITDA
$112.51M
Free cash flow
$142.8M
Per share
EPS
$0.86
Free cash flow per share
$1.22
Book value per share
$4.35
Revenue per share
$2.91
TBVPS
$4.73
Balance sheet
Total assets
$552.4M
Total liabilities
$41.6M
Debt
$2.07M
Equity
$510.8M
Working capital
$369.02M
Liquidity
Debt to equity
0
Current ratio
10.09
Quick ratio
9.73
Net debt/EBITDA
-0.45
Margins
EBITDA margin
33.1%
Gross margin
98.5%
Net margin
29.2%
Operating margin
32.4%
Efficiency
Return on assets
18.4%
Return on equity
20.1%
Return on invested capital
24.8%
Return on capital employed
21.5%
Return on sales
32.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
-0.15%
1 week
0.45%
1 month
-8.85%
1 year
24.86%
YTD
-22.44%
QTD
-7.77%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$340.06M
Gross profit
$335.09M
Operating income
$110.13M
Net income
$99.41M
Gross margin
98.5%
Net margin
29.2%
The operating margin has contracted by 17% YoY and by 10% from the previous quarter
Corcept Therapeutics's operating income has decreased by 16% YoY and by 14% from the previous quarter
Corcept Therapeutics's net margin has decreased by 8% YoY and by 2.7% QoQ
CORT's net income is down by 6% QoQ and by 6% YoY

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
P/E
23.59
P/B
4.66
P/S
6.97
EV/EBIT
21.03
EV/EBITDA
20.59
EV/Sales
6.81
The P/E is 38% less than the 5-year quarterly average of 38.3 but 3% more than the last 4 quarters average of 22.9
The EPS has declined by 7% since the previous quarter and by 7% year-on-year
The stock's price to book (P/B) is 54% less than its 5-year quarterly average of 10.1 and 4.9% less than its last 4 quarters average of 4.9
The company's equity rose by 25% YoY but it fell by 2.4% QoQ
CORT's P/S is 16% below its 5-year quarterly average of 8.3
The revenue has declined by 3.9% since the previous quarter

Efficiency

How efficient is Corcept Therapeutics business performance
CORT's ROIC is down by 43% year-on-year and by 21% since the previous quarter
CORT's return on assets is down by 33% year-on-year and by 11% since the previous quarter
The return on equity has declined by 33% year-on-year and by 11% since the previous quarter
The return on sales has declined by 17% year-on-year and by 10% since the previous quarter

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The company's total assets rose by 24% YoY but it fell by 3.4% QoQ
The total liabilities has grown by 16% YoY but it has contracted by 14% from the previous quarter
Corcept Therapeutics's debt is 100% lower than its equity
CORT's debt to equity has shrunk by 100% YoY
Corcept Therapeutics's debt has decreased by 34% YoY and by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.